Blood Based Biomarkers Market - 2026-2035

July 2026 | 48 pages | ID: B3A072008C9CEN
DataM Intelligence

Abstracts

Blood Based Biomarkers Market reached US$ 10.78 billion in 2025 and is expected to reach US$ 41.43 billion by 2035, growing with a CAGR of 14.20% during the forecast period 2026-2035.

The Blood Based Biomarkers Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Blood Based Biomarkers Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Biomarker Type

• Genomic Biomarkers*
• Proteomic Biomarkers
• Metabolomic Biomarkers
• Epigenetic Biomarkers
• Cell Free DNA
• Circulating Tumor DNA
• Circulating Tumor Cells
• Multi Biomarker Panels
• Others

By Disease Area

• Oncology*
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Hematologic Cancer
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Diseases
• Autoimmune Diseases
• Metabolic Disorders
• Prenatal Health
• Others

By Application

• Screening*
• Diagnosis
• Risk Stratification
• Prognosis
• Therapy Selection
• Companion Diagnostics
• Treatment Monitoring
• Recurrence Monitoring

By Technology

• PCR*
• NGS
• Targeted Sequencing
• Whole Genome Sequencing
• Whole Exome Sequencing
• ELISA
• Immunoassays
• Mass Spectrometry
• Proteomics Platforms
• Others

By Sample Type

• Plasma*
• Serum
• Whole Blood

By End User

• Hospitals*
• Diagnostic Laboratories
• Cancer Centers
• Pharma and Biotechnology Companies
• CROs
• Research Institute

Regional Analysis for Blood Based Biomarkers Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Blood Based Biomarkers Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Data
  1.1.1. Secondary Data
  1.1.2. Primary Data
  1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
  1.2.1. Bottom-Up Approach
  1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations

2. DEFINITION AND OVERVIEW

2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period

3. EXECUTIVE SUMMARY

3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Rising Shift Toward Minimally Invasive Diagnostics
    4.1.1.2. Growing Demand for Early Disease Detection
    4.1.1.3. Expansion of Precision Medicine and Companion Diagnostics
  4.1.2. Restraints
    4.1.2.1. Clinical Validation and Reimbursement Challenges
    4.1.2.2. High Cost of Advanced Biomarker Platforms
  4.1.3. Impact Analysis - Drivers and Restraints
  4.1.4. Opportunity
    4.1.4.1. Growth in Multi Cancer Early Detection Testing
    4.1.4.2. Emerging Use in Neurological Disorders
  4.1.5. Trends
    4.1.5.1. AI Enabled Multi Biomarker Interpretation
    4.1.5.2. Shift From Single Biomarker Tests to Multi Biomarker Panels
  4.1.6. Challenges
    4.1.6.1. Low Clinical Utility for Some Emerging Biomarkers
    4.1.6.2. Data Interpretation Complexity

5. INDUSTRY ANALYSIS

5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors
  5.3.1. Rising patient preference for minimally invasive testing is increasing adoption of blood based biomarker diagnostics
  5.3.2. Growing awareness of early disease detection is encouraging preventive screening for cancer, cardiovascular diseases and neurological disorders
  5.3.3. Increasing acceptance of personalized medicine is supporting demand for biomarker guided diagnosis, therapy selection and treatment monitoring
5.4. Economic Factors
  5.4.1. Rising healthcare spending on precision diagnostics is creating sustained demand for advanced blood based biomarker platforms
  5.4.2. Growing investment by pharma and biotech companies in companion diagnostics is expanding commercial use of blood based biomarkers
  5.4.3. Increasing cost burden of late stage disease treatment is pushing healthcare systems toward early detection and routine monitoring solutions
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Technology Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion

6. BY BIOMARKER TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  6.1.2. Market Attractiveness Index, By Biomarker Type
6.2. Genomic Biomarkers*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Proteomic Biomarkers
6.4. Metabolomic Biomarkers
6.5. Epigenetic Biomarkers
6.6. Cell Free DNA
6.7. Circulating Tumor DNA
6.8. Circulating Tumor Cells
6.9. Multi Biomarker Panels
6.10. Others

7. BY DISEASE AREA

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  7.1.2. Market Attractiveness Index, By Disease Area
7.2. Oncology*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  7.2.3. Breast Cancer
  7.2.4. Lung Cancer
  7.2.5. Colorectal Cancer
  7.2.6. Prostate Cancer
  7.2.7. Hematologic Cancer
7.3. Cardiovascular Diseases
7.4. Neurological Disorders
7.5. Infectious Diseases
7.6. Autoimmune Diseases
7.7. Metabolic Disorders
7.8. Prenatal Health
7.9. Others

8. BY APPLICATION

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  8.1.2. Market Attractiveness Index, By Application
8.2. Screening*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Diagnosis
8.4. Risk Stratification
8.5. Prognosis
8.6. Therapy Selection
8.7. Companion Diagnostics
8.8. Treatment Monitoring
8.9. Recurrence Monitoring

9. BY TECHNOLOGY

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  9.1.2. Market Attractiveness Index, By Technology
9.2. PCR*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. NGS
  9.3.1. Targeted Sequencing
  9.3.2. Whole Genome Sequencing
  9.3.3. Whole Exome Sequencing
9.4. ELISA
9.5. Immunoassays
9.6. Mass Spectrometry
9.7. Proteomics Platforms
9.8. Others

10. BY SAMPLE TYPE

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  10.1.2. Market Attractiveness Index, By Sample Type
10.2. Plasma*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Serum
10.4. Whole Blood

11. BY END USER

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  11.1.2. Market Attractiveness Index, By End User
11.2. Hospitals*
  11.2.1. Introduction
  11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Diagnostic Laboratories
11.4. Cancer Centers
11.5. Pharma and Biotechnology Companies
11.6. CROs
11.7. Research Institute

12. BY REGION

12.1. Introduction
  12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  12.1.2. Market Attractiveness Index, By Region
12.2. North America*
  12.2.1. Introduction
  12.2.2. Key Region-Specific Dynamics
  12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  12.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

13. U.S.

13.1. Canada
  13.1.1. Mexico
13.2. Europe
  13.2.1. Introduction
  13.2.2. Key Region-Specific Dynamics
  13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  13.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    13.2.9.1. Germany
    13.2.9.2. UK
    13.2.9.3. France
    13.2.9.4. Russia
    13.2.9.5. Spain
    13.2.9.6. Italy
    13.2.9.7. Poland
    13.2.9.8. Rest of Europe
13.3. Latin America
  13.3.1. Introduction
  13.3.2. Key Region-Specific Dynamics
  13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  13.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  13.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    13.3.9.1. Brazil
    13.3.9.2. Argentina
    13.3.9.3. Rest of Latin America
13.4. Asia-Pacific
  13.4.1. Introduction
  13.4.2. Key Region-Specific Dynamics
  13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  13.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  13.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    13.4.9.1. China
    13.4.9.2. India
    13.4.9.3. Japan
    13.4.9.4. Australia
    13.4.9.5. South Korea
    13.4.9.6. Indonesia
    13.4.9.7. Malaysia
    13.4.9.8. Rest of Asia-Pacific
13.5. Middle East and Africa
  13.5.1. Introduction
  13.5.2. Key Region-Specific Dynamics
  13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
  13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Area
  13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
  13.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  13.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    13.5.9.1. UAE
    13.5.9.2. Saudi Arabia
    13.5.9.3. South Africa
    13.5.9.4. Israel
    13.5.9.5. Turkiye
    13.5.9.6. Rest of Middle East and Africa

14. COMPETITIVE LANDSCAPE

14.1. Competitive Scenario
14.2. Market Share Analysis - Global
14.3. Market Share Analysis - North America
14.4. Market Share Analysis - Europe
14.5. Market Share Analysis - Asia-Pacific
14.6. Mergers and Acquisitions Analysis
14.7. Partner Identification Analysis
14.8. Investment & Funding Landscape
14.9. Strategic Alliances & Innovation Pipeline

15. COMPANY PROFILES

15.1. Guardant Health, Inc.*
  15.1.1. Company Overview
  15.1.2. Product Portfolio and Description
  15.1.3. Revenue Analysis
  15.1.4. Pricing Analysis
  15.1.5. SWOT Analysis
  15.1.6. Recent Developments
    15.1.6.1. Major Deals
    15.1.6.2. M&A
    15.1.6.3. Collaboration
    15.1.6.4. Acquisition
    15.1.6.5. Joint Ventures
    15.1.6.6. Innovations
  15.1.7. Recent News
    15.1.7.1. Events
    15.1.7.2. Conferences
    15.1.7.3. Symposiums
    15.1.7.4. Webinars

16. GRAIL, INC.

16.1. Natera, Inc.
16.2. Foundation Medicine, Inc.
16.3. F. Hoffmann-La Roche Ltd
16.4. Thermo Fisher Scientific Inc.
16.5. QIAGEN
16.6. Abbott
16.7. Siemens Healthcare Private Limited
16.8. bioM?rieux
16.9. Beckman Coulter, Inc
16.10. Illumina, Inc.
16.11. Bio-Rad Laboratories, Inc.
16.12. Sysmex Europe SE.
16.13. Freenome Holdings, Inc.
16.14. Labcorp
16.15. Quest Diagnostics Incorporated.
16.16. Exact Sciences Corporation.
16.17. Tempus
16.18. Personalis, Inc. (LIST NOT EXHAUSTIVE)

17. APPENDIX

17.1. About Us and Services
17.2. Contact Us